Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic
  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Apollomics Starts China Trial of Immunotherapy for AML

Apollomics, a Bay Area-Hangzhou biopharma, started a China Phase I trial of uproleselan in patients with relapsed or refractory acute myeloid leukemia (AML). In 2020, Apollomics acquired China rights to uproleselan from GlycoMimetics in a two-drug, $189 million deal. Both drugs are novel E-selectin-based immunotherapies aimed at leukemia. Uproleselan is designed to block E-selectin from binding with blood cancer cells, which causes drug resistance. It will be administered along with chemotherapy. Apollomics was incubated by OrbiMed Asia to develop cancer immunotherapies. More details.... Stock Symbol: (NSDQ: GLYC) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.